Hyperbaric Therapy and Deep Chemical Peeling
Recruitment status was Recruiting
To evaluate whether treatment with Hyperbaric oxygen can accelerate skin recovery after deep peeling, and decrease frequency and severity of local side effects and complications.
20 post peel patients will recieve 5 daily hyperbaric treatments, starting from day 7 to peel.Patient's followup will include self- filling questionnaire and photographs
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Hyperbaric Therapy and Healing From Deep Chemical Peel|
|Study Start Date:||January 2007|
|Estimated Study Completion Date:||July 2007|
The study will include 40 post-deep peel women (exoderm), older than 18 years old, treated by the same dermatologist.
The treatment group will recieve 5 consecutive daily hyperbaric treatments, 1 hours long each, at 2 ATF, starting from day 7 to peel. Prior to treatment, each patient will be signed on informed consent and will have complete physical examination.
The control group will be matched by the following parameters: age, skin color and type, and indication for peeling, and will be picked up by the dermatologist.
Patients will be excluded if they have known middle ear disease, chronic lung disease or claustrophobia.
The same dermatologist will follow-up, on regular dates: the follow-up examination will start at day 1 to mask\occlusive dressing removal (equivalent to day 7 post-peel), and at days 7, 28, and after 3 months. All follow-up examinations will take place at noon (04-08 pm) regularly.
All patients will be asked to fill up a daily questionnaire on the first week after peel, and score the severity of pain, pruritus and tightness of facial skin (1 to 5). They will also mention the daily analgesic usage.
Parameters that will be evaluated by the dermatologist during the study will be: tightness of the skin, pain/burning, pruritus/stinging, swelling/edema, erythema, crusting, and scaling, assessed on a 4-point severity scale (0- best, 3- worst).
Photographs of the patients in 5 angles views will be taken on the day of peel, day of mask removal (7), day 28 and after 3 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00425789
|Contact: Tal Friedman, MDfirstname.lastname@example.org|
|Contact: Shai Efrati, MDemail@example.com|
|Research & Development Unit, Assaf-Harofeh Medical Center||Recruiting|
|Zerifin, Israel, 70300|
|Contact: Tal Friedman, MD +972-574-225961 firstname.lastname@example.org|
|Contact: Shai Efrati, MD +972-577-346364 email@example.com|
|Principal Investigator: Tal Friedman, MD|
|Principal Investigator:||Tal Friedman, MD||Assaf-Harofeh Medical Center|
|Study Director:||Shai Efrati, MD||Assaf-Harofeh Medical Center|